Table 3.
Patient characteristics in [177Lu]Lu-DOTA-TATE (ERASMUS) before and after matching to the RADIANT-4 GI subgroup.
| Patient characteristic | ERASMUS (pre-match) |
ERASMUS (post-match everolimus) |
RADIANT-4 (GI only) |
ERASMUS (post-match BSC) |
RADIANT-4 (GI only) |
|
|---|---|---|---|---|---|---|
| [177Lu]Lu-DOTA-TATE | [177Lu]Lu-DOTA-TATE | Everolimus | [177Lu]Lu-DOTA-TATE | BSC | ||
| N | N | 111 | 111 | 118 | 111 | 57 |
| Effective sample size: | 105 | 95 | ||||
| Sex | Male | 55% | 53% | 41% | 52% | 55% |
| Female | 45% | 47% | 59% | 48% | 45% | |
| ECOG performance status | 0 | 64% | 75% | 75% | 84% | 84% |
| 1 | 36% | 25% | 25% | 16% | 16% | |
| Previous chemotherapy | Yes | 6% | 7% | 19% | 7% | 12% |
| No | 94% | 93% | 81% | 93% | 88% | |
| Age (years) | Mean (median) | 61 | 61 | NA (63) | 61 | NA (60) |
| Previous surgery | Yes | 54% | 56% | 70% | 57% | 63% |
| No | 46% | 44% | 30% | 43% | 37% | |
| Prior SSA use |
Yes | 78% | 78% | 59% | 78% | 63% |
| No | 22% | 22% | 41% | 22% | 37% | |
| Weightsa | Mean | 1.00 | 1.00 | |||
| Range | (0.69–1.17) | (0.44–1.31) |
BSC, best supportive care; GI, gastrointestinal; SSA, somatostatin analogue; ECOG, Eastern Cooperative Oncology Group; NA, not available.
Tumour functionality and time from disease progression to randomisation are not available from either comparator trial so not included in the table.
a
A histogram describing the full distribution of weights is provided in the data supplement.